Revolution Medicines drug RMC-6236 increased progression-free survival in patients with advanced cases of pancreatic ductal adenocarcinoma. With these results, the biotech is preparing for a Phase 3 clinical trial in this indication, the most common type of pancreatic cancer.
Ipsen’s Onivyde is now FDA approved as a first-line treatment for metastatic pancreatic cancer, triggering a milestone payment to Merrimack Pharmaceuticals, the drug’s original developer. Merrimack plans to dissolve operations but its shareholders will receive payouts from the Ipsen payment.
The future looks bright for the integrated specialty pharmacy model – for health systems, providers, and most importantly, for patients.
Researchers at the University of Texas MD Anderson Cancer Center published two studies this week on a new approach that could improve treatment for patients with pancreatic cancer. The preclinical studies showed that combining immunotherapy with a KRAS inhibitor can lead to long-lasting tumor elimination.
Targeted drugs and immunotherapies are among the advances that contribute to declines in incidence and deaths from non-small cell lung cancer, according to the Annual Report to the Nation on the Status of Cancer. But the trends are on the rise for some other cancers and racial disparities persist, highlighting the need to better understand these differences.
Researchers at the University of Texas MD Anderson Cancer Center published a new study revealing that cancer cells make their own unique form of collagen to help them grown and proliferate. This means drug developers may have a new, highly specific target for oncology therapeutics.
Cancer drug developer Merus has encouraging early results indicating its drug can address several different types of tumors characterized by NRG1, a rare gene fusion. The company believes the data could support a regulatory filing for the bispecific antibody drug.
Closing cancer health equity gaps require medical breakthroughs made possible by new funding approaches.
Loki Therapeutics is advancing research that leverages the immune system's ability to recall childhood vaccinations and direct it against cancer. The company's lead therapy candidate could enter phase 1 clinical trials this year.
Amplified Sciences emerged as the winner of the diagnostics track for the MedCity INVEST conference's Pitch Perfect contest with PanCystPro, the test it is developing to address the problems encountered when determining whether pancreatic cysts are cancerous.
BMS told Five Prime that it does not have current plans to further sponsor clinical development of the drug cabiralizumab after the failure of the combo trial, with BMS' Opdivo and chemotherapy, but would support some investigator-sponsored trials.
The FDA approved Lynparza for patients with pancreatic cancer after chemotherapy whose tumors harbor a certain genetic mutation.
The progress in artificial intelligence (AI) is reshaping patient care, across various dimensions, from facilitating faster discharge to curating treatment plans and suggesting lifestyle changes.
The biotech company will shut down its development program for PEGPH20 and instead focus on its drug delivery technology program while laying off 55 percent of its workforce.
As part of a new research collaboration, Memorial Sloan Kettering Cancer Center and Philips will be using DNA sequencing technologies to better understand pancreatic cancer.
Following two small Phase 1 trials, Cornerstone Pharmaceuticals announced Thursday that it has secured FDA-backing for pivotal trials of its lead drug in AML and late-stage pancreatic cancer.
The scientific advisory board's role is to ensure the information shared on the website is scientifically based and that it offers a potential option beyond the existing standard of care treatments.
Former Biogen R&D chief Doug Williams is launching a biotech startup called Codiak BioSciences with $80 million. It is developing exosomes as a new diagnostic and therapeutic tool, beginning with pancreatic cancer.